CRISPR-Cas9 gene edits last for a year in mouse model of DMD

Duke University researchers reported that CRISPR-Cas9-mediated gene editing treated Duchenne muscular dystrophy in mice through one year, and described findings that suggest treating neonates could help avoid immunity against CRISPR-associated protein 9 (Cas9).

Sarepta

Read the full 334 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE